| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
|---|---|
| MLF | Median Longitudinal Fasciculus Role; links the CN III Nucleus with Contralateral CN ... |
| AI, AII, AIII | angiotensin I, II, III |
| CIN | 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ) |
| CONPA-DRI | III conpa-dri I plus intensified doxorubicin |
| arteriae intercostales posteriores III-XI | posterior intercostal arteries 3-11 |
|---|---|
| band III protein | <protein> A 90 kD protein embedded in the surface of the human erythrocyte membrane, identified as the major anion transport/exchange protein. When the red blood cell is in the lungs, brings chlorine ion into the cell in exchange for bicarbonate. Analogous proteins exist in other erythrocytes. A dimeric transmembrane glycoprotein, with binding sites for many cytolasmic proteins, including ankyrin, on its cytoplasmic domain. (18 Nov 1997) |
| palpebra III | The semilunar fold formed by the palpebral conjunctiva at the medial angle of the eye, a fold of the conjunctival mucous membrane found in many animals; normally partially hidden in the medial canthus of the eye when at rest, it may be extended to cover part or all of the cornea in a winking-like action to clean the cornea, as in birds. Synonym: membrana nictitans, nictitating membrane, palpebra III, palpebra tertia, third eyelid. Synonym: plica lunata, plica semilunaris of eye, semilunar conjunctival fold. (05 Mar 2000) |
| ramus collateralis arteriarum intercostalium posteriorum III-XI | Branch arising near angle of rib and descending to run along superior border of rib below; distribution: lower half of intercostal spaces 3-11; anastomoses: collateral branches of anterior intercostal arteries. Synonym: ramus collateralis arteriarum intercostalium posteriorum III-XI. (05 Mar 2000) |
| ramus cutaneus medialis rami dorsalis arteriarum intercostalium posteriorum III-XI | Medial cutaneous branch of dorsal branch of posterior intercostal arteries. See: medial cutaneous branch. (05 Mar 2000) |
| ramus dorsalis arteriarum intercostalium posteriorum III-XI | Terminal branch (with ventral branch) of the 3rd through 11th posterior intercostal arteries, distributed to thoracic portion of posterior vertebral column, spinal cord and environs, and back. Synonym: ramus dorsalis arteriarum intercostalium posteriorum III-XI. (05 Mar 2000) |
| virus III of rabbits | An obsolete name for a latent herpesvirus infection of rabbits. Origin: the third strain isolated, used for study (05 Mar 2000) |
| glycogen storage disease type III | <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system). The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent. Inheritance: autosomal recessive (12 Dec 1998) |
| grade III astrocytoma | <tumour> Astrocytoma of intermediate grade. See: glioblastoma multiforme. (05 Mar 2000) |
| group III mycobacteria | Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare. Synonym: nonchromogens. (05 Mar 2000) |
| RNA polymerase III | <enzyme> A DNA-dependent RNA polymerase present in bacterial, plant, and animal cells. It functions in the nucleoplasmic structure where it transcribes DNA into RNA. It has specific requirements for cations and salt and has shown an intermediate sensitivity to alpha-amanitin in comparison to RNA polymerase I and II. Registry number: EC 2.7.7.- (12 Dec 1998) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| clinical trial, phase III | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trials, phase III | Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries. (12 Dec 1998) |
| mucolipidosis III | <biochemistry> Mucolipidosis with mild Hurler-like symptoms, restricted joint mobility, short stature, mild mental retardation, and dysplastic skeletal changes, especially of the hip. Aortic and mitral valve disease are often present. It is associated with a deficiency of UDP-N-acetyl glucosamine and lysosomal enzyme N-acetylglucosaminyl-1-phosphotransferase. Inheritance: autosomal recessive. Synonym: pseudo-Hurler polydystrophy, pseudopolydystrophy. (05 Mar 2000) |